All articles tagged with #lpa
Researchers are nearing the completion of clinical trials for five experimental drugs aimed at lowering lipoprotein(a), a genetic particle linked to artery clogging and heart disease, with results expected in 2026. These drugs could significantly impact the treatment of a condition affecting about 20% of the global population, though cost and public awareness remain challenges.
A Staten Island cardiologist highlights the importance of testing for lipoprotein(a) or Lp(a), a genetic cholesterol marker that increases the risk of heart attack and stroke, which is often overlooked and not affected by diet or exercise, emphasizing early detection and management for better heart health.
A new pill called Obicetrapib significantly lowers 'bad' LDL cholesterol and lipoprotein(a) levels in just 12 weeks, offering a promising treatment for high-risk heart patients, with results showing over 30% reduction and good tolerability.
Doctors warn that up to 65 million Americans may be at risk of deadly stroke or heart attack due to high levels of a specific type of cholesterol called lipoprotein(a), which is determined almost entirely by genetics and currently has no approved treatments. High levels of Lp(a) can lead to a two- to three-fold higher risk of heart attack and a nearly two-fold increased risk of stroke, often occurring at a relatively young age. Comprehensive cholesterol testing is being called for to detect high levels of Lp(a) and help patients mitigate their risks, while pharmaceutical companies are developing treatments to lower Lp(a) levels.
Lipoprotein(a) or Lp(a) is a genetic risk factor that greatly increases the chances of a heart attack when present in high levels in the blood. Lp(a) causes atherosclerosis, inflammation, and increases the risk of clotting, making it a triple threat for heart disease. Approximately 20% of the population, particularly Black and South Asian Americans, are at risk due to Lp(a), yet fewer than 1% of Americans have had their levels checked. While there is currently no therapeutic available to directly reduce Lp(a), testing levels can help individuals mitigate overall cardiovascular risk by focusing on reducing other risk factors. Researchers are working on developing drugs to treat high Lp(a) levels, and clinical trials are underway.
Lipoprotein(a) or Lp(a) is a protein that significantly increases the risk of heart attack when present in high levels in the blood. Lp(a) causes atherosclerosis, inflammation, and increases the risk of clotting, making it a triple threat for heart disease. Approximately 20% of the population, particularly Black and South Asian Americans, are at risk due to Lp(a), yet fewer than 1% of Americans have had their levels checked. While there is currently no therapeutic available to directly reduce Lp(a), it is important to reduce other cardiovascular risk factors. Testing Lp(a) levels can help individuals mitigate overall risk and make informed decisions about their health. Researchers are working on developing drugs to treat high Lp(a) levels, and lipoprotein apheresis is available for a small number of high-risk patients.
An experimental drug called lepodisiran has shown promising results in reducing blood levels of lipoprotein(a) (Lp(a)), a currently untreatable risk factor for heart disease. In a phase 1 trial, a single injection of lepodisiran lowered participants' high Lp(a) levels by as much as 96% from their baseline. Lepodisiran works by interfering with the genetic material that produces Lp(a), offering a potential solution for individuals with high Lp(a) levels who are unable to reduce this risk factor through lifestyle changes. Further trials are needed to confirm the drug's safety and effectiveness, but the initial results are encouraging.